2024, 2023, 2022, 2021, 2020, 2019, 2018, 2017, 2016, 2015, 2014, 2013, 2012, 2011, 2010, 2009, 2008, 2006, 2005, 2003

2024

  1. Terui S, Igari M, Tsuno T, Okuyama T, Inoue R, Kyohara M, Terauchi Y, *ShirakawaJ. Immediate impact of switching from dipeptidyl peptidase-4 (DPP-4) inhibitors to low-dose (0.3 mg) liraglutide on glucose profiles: A retrospective observational study. Diabetes Ther. in press, 2024.
  2. Nishida J, Tsuno T, G Yabe S, Kin T, Fukuda S, Takeda F, Shirakawa J, Okochi H. Encapsulated human islets in alginate fiber maintain long-term functionality. Endocr J. 71(3):253-264, 2024.

*: corresponding author

2023

  1. *Shirakawa J. Signaling pathways that regulate adaptive β-cell proliferation for the treatment of diabetes. J Diabetes Investig. 14(6):735-740, 2023.
  2. Fukunaka A, Shimura M, Ichinose T, Pereye OB, Nakagawa Y, Tamura Y, Mizutani W, Inoue R, Inoue T, Tanaka Y, Sato T, Saitoh T, Fukada T, Nishida Y, Miyatsuka T, Shirakawa J, Watada H, Matsuyama S, Fujitani Y. Zinc and iron dynamics in human islet amyloid polypeptide-induced diabetes mouse model. Sci Rep. 13(1):3484, 2023.
  3. Arai M, Tsuno T, Konishi H, Nishiyama K, Terauchi Y, Inoue R, *Shirakawa J. A disproportionality analysis of the adverse effect profiles of methimazole and propylthiouracil in patients with hyperthyroidism using the Japanese Adverse Drug Event Report Database. Thyroid. 33(7):804-816, 2023.
  4. #Nishiyama K, #Ono M, Tsuno T, Inoue R, Fukunaka A, Okuyama T, Kyohara M, Togashi Y, Fukushima S, Atsumi T, Sato A, Tsurumoto A, Sakai C, Fujitani Y, Terauchi Y, Ito S, *Shirakawa J. Protective effects of imeglimin and metformin combination therapy on β-cells in db/db male mice. Endocrinology. 164(8):bqad095, 2023.
  5. Moon S, Alsarkhi L, Lin TT, Inoue R, Tahiri A, Colson C, Cai W, Shirakawa J, Qian WJ, Zhao JY, El Ouaamari A. Transcriptome and secretome profiling of sensory neurons reveals sex differences in pathways relevant to insulin sensing and insulin secretion. FASEB J. 37(10):e23185, 2023.

*: corresponding author

#: co-first author

2022

  1. Li J, Inoue R, Togashi Y, Okuyama T, Satoh A, Kyohara M, Nishiyama K, Tsuno T, Miyashita D, Kin T, Shapiro AJM, Chew RSE, Teo AKK, Oyadomari S, Terauchi Y, *Shirakawa J. Imeglimin ameliorates β-cell apoptosis by modulating the endoplasmic reticulum homeostasis pathway. Diabetes. 71(3):424-439, 2022.
  2. Minami T, Shirakawa J, Hiiragi H, Yamada T, Suzuki Y, Shirabe S, Maeda H, Terauchi Y. Validity and reliability of the Japanese version of the Diabetes Knowledge Test among in-patients with type 2 diabetes. J Diabetes Investig. 13(3):580-587, 2022.
  3. Halperin F, Mezza T, Li P, Shirakawa J, Kulkarni RN, Goldfine AB. Insulin regulates arginine-stimulated insulin secretion in humans. Metabolism. 128:155117, 2022.
  4. *Hirano H, *Shirakawa J. Recent developments in Phos-tag electrophoresis for the analysis of phosphoproteins in proteomics. Expert Rev Proteomics. 19(2):103-114, 2022.
  5. Sobajima M, Miyake M, Hamada Y, Tsugawa K, Oyadomari M, Inoue R, Shirakawa J, Arima H, Oyadomari S. The multifaceted role of ATF4 in regulating glucose-stimulated insulin secretion. Biochem Biophys Res Commun. 611:165-171, 2022.
  6. Inoue R, Tsuno T, Togashi Y, Okuyama T, Sato A, Nishiyama K, Kyohara M, Li J, Fukushima S, Kin T, Miyashita D, Shiba Y, Atobe Y, Kiyonari H, Bando K, Shapiro AMJ, Funakoshi K, Kulkarni RN, Terauchi Y, *Shirakawa J. Uncoupling protein 2 and aldolase B impact insulin release by modulating mitochondrial function and Ca2+ release from the ER. iScience. 25(7):104603, 2022.
  7. Togashi Y, Miyashita D, Tsuno T, Inoue R, Okuyama T, Kyohara M, Nishiyama K, Arai M, Kanematsu K, Kanataki S, Terauchi Y, *Shirakawa J. Abdominal aortic calcification is associated with Fibrosis-4 index and low body mass index in type 2 diabetes patients: A retrospective cross-sectional study. J Diabetes Investig. 13(11):1861-1872, 2022.
  8. *Shirakawa J, Togashi Y, Basile G, Okuyama T, Inoue R, Fernandez M, Kyohara M, De Jesus DF, Goto N, Zhang W, Tsuno T, Kin T, Pan H, Dreyfuss JM, Shapiro AMJ, Yi P, Terauchi Y, Kulkarni RN. E2F1 transcription factor mediates a link between fat and islets to promote β-cell proliferation in response to acute insulin resistance. Cell Rep. 41(1):111436, 2022.
  9. Kyohara M, Miyashita D, Inoue R, Nishiyama K, Tsuno T, Okuyama T, Togashi Y, Terauchi Y, *Shirakawa J. Association between circulating SerpinB1 levels and insulin sensitivity in Japanese with type 2 diabetes: A single-center, cross-sectional, observational study. PLoS One. 17(11):e0276915, 2022.
  10. #Miyashita D, #Inoue R, Tsuno T, Okuyama T, Kyohara M, Nakahashi-Oda C, Nishiyama K, Fukushima S, Inada Y, Togashi Y, Shibuya A, Terauchi Y, *Shirakawa J. Protective effects of S100A8 on sepsis mortality: links to sepsis risk in obesity and diabetes. iScience. 25(12):105662, 2022.

*: corresponding author

#: co-first author

2021

  1. Charoensuk C, Thamtarana PJ, Chanprasert C, Tangjittipokin W, Shirakawa J, Togashi Y, Orime K, Songprakhon P, Chaichana C, Abubakar Z, Ouying P, Sujjitjoon J, Doria A, Plengvidhya N, Yenchitsomanus PT. Autosomal Dominant Diabetes Associated with a Novel ZYG11A Mutation Resulting in Cell Cycle Arrest in Beta-Cells. Mol Cell Endocrinol. 522:111126, 2021.
  2. Okuyama T, *Shirakawa J, Nakamura T, Murase T, Miyashita D, Inoue R, Kyohara M, Togashi Y, Terauchi Y. Association of the plasma xanthine oxidoreductase activity with the metabolic parameters and vascular complications in patients with type 2 diabetes. Sci Rep. 11(1):3768, 2021.
  3. #Takatani T, #Shirakawa J, #Shibue K, Gupta MK, Kim H, Lu S, Hu J, White MF, Kennedy RT, Kulkarni RN. Insulin receptor substrate 1, but not IRS2, plays a dominant role in regulating pancreatic alpha cell function in mice. J Biol Chem. 296:100646, 2021.
  4. Inoue R, Nishiyama K, Li J, Miyashita D, Ono M, Terauchi Y, *Shirakawa J. The Feasibility and Applicability of Stem Cell Therapy for the Cure of Type 1 Diabetes. Cells. 10(7):1589, 2021.
  5. Okuyama T, Kyohara M, Terauchi Y, *Shirakawa J. The Roles of the IGF Axis in the Regulation of the Metabolism: Interaction and Difference between Insulin Receptor Signaling and IGF-I Receptor Signaling. Int J Mol Sci. 22(13):6817, 2021.
  6. Hasebe M, *Shirakawa J, Miyashita D, Kunishita R, Kyohara M, Okuyama T, Togashi Y, Terauchi Y. Asymptomatic meningitis diagnosed by positron emission tomography in a patient with syndrome of inappropriate antidiuretic hormone secretion: a case report. J Med Case Rep. 15(1):390, 2021.
  7. *Shirakawa J. Translational research on human pancreatic β-cell mass expansion for the treatment of diabetes. Diabetol Int. 12(4):349-355, 2021.
  8. Terui S, Akamatsu R, Arai M, Inoue R, Okuyama T, Kyohara M, Li J, Tsuno T, Miyashita D, Togashi Y, Terauchi Y, *Shirakawa J. Immediate glucose-lowering effect after the first administration of dulaglutide: a retrospective, single-center, observational study. Diabetes Ther. 12(11):2873-2889, 2021.
  9. *Shirakawa J. Pancreatic β-cell fate in subjects with COVID-19. J Diabetes Investig. 12(12):2126-2128, 2021.

*: corresponding author

#: co-first author

2020

  1. *Shirakawa J , Terauchi Y. Newer perspective on the coupling between glucose-mediated signaling and β-cell functionality. Endocr J. 67(1):1-8, 2020.
  2. *Shirakawa J , Tajima K, Okuyama T, Kyohara M, Togashi Y, De Jesus DF, Basile G, Kin T, Shapiro AMJ, Kulkarni RN, Terauchi Y. Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway. Diabetologia. 63(3):577-587, 2020.
  3. Shirakawa J, Terauchi Y. Potential linkage between DPP-4 inhibitor use and the risk of pancreatitis/pancreatic cancer. J Diabetes Investig. 11(4):789-791, 2020. 
  4. Wang H, Mizuno K, Takahashi N, Kobayashi E, Shirakawa J, Terauchi Y, Kasai H, Okunishi K, Izumi T. Melanophilin accelerates insulin granule fusion without predocking to the plasma membrane. Diabetes. 69(12):2655-2666, 2020.
  5. Kyohara M, *Shirakawa J, Okuyama T, Togashi Y, Inoue R, Li J, Miyashita D, Terauchi Y. Soluble EGFR, a hepatokine, and adipsin, an adipokine, are biomarkers correlated with distinct aspects of insulin resistance in type 2 diabetes subjects. Diabetol Metab Syndr. 12:83, 2020.
  6. Okuyama T, *Shirakawa J, Tajima K, Ino Y, Vethe H, Togashi Y, Kyohara M, Inoue R, Miyashita D, Li J, Goto N, Ichikawa T, Yamasaki S, Ohnuma H, Takayanagi R, Kimura Y, Hirano H, Terauchi Y. Linagliptin Ameliorates Hepatic Steatosis via Non-Canonical Mechanisms in Mice Treated with a Dual Inhibitor of Insulin Receptor and IGF-1 Receptor. Int J Mol Sci. 21(21):E7815, 2020.
  7. Gupta MK, Vethe H, Softic S, Rao TN, Wagh V, Shirakawa J, Barsnes H, Vaudel M, Takatani T, Kahraman S, Sakaguchi M, Martinez R, Hu J, Bjørlykke Y, Raeder H, Kulkarni RN. Leptin Receptor Signaling Regulates Protein Synthesis Pathways and Neuronal Differentiation in Pluripotent Stem Cells. Stem Cell Reports. 15(5):1067-1079, 2020.
  8. Minami T, Shirakawa J, Suzuki Y, Nezu Osada U, Kameda A, Watanabe K, Yamada T, Hiiragi H, Takeda S, Takahashi M, Terauchi Y. A case of an elderly patient with insulin-dependent diabetes and dementia receiving bolus and basal insulin therapy once a day for 6 months. Diabetol Int. 12(1):135-139, 2020.

*: corresponding author

2019

  1. #El Ouaamari A, #O-Sullivan I, #Shirakawa J, Basile G, Zhang W, Roger S, Thomou T, Xu S, Qiang G, Liew CW, Kulkarni RN, Unterman TG. Forkhead box protein O1 (FoxO1) regulates hepatic serine protease inhibitor B1 (serpinB1) expression in a non-cell-autonomous fashion. J Biol Chem. 294(3):1059-1069, 2019.  
  2. Jungtrakoon P, Shirakawa J, Buranasupkajorn P, Gupta MK, De Jesus DF, Pezzolesi MG, Panya A, Hastings T, Chanprasert C, Mendonca C, Kulkarni RN, Doria A. Loss-of-function mutation in thiamine transporter 1 in a family with autosomal dominant diabetes. Diabetes. 68(5):1084-1093, 2019.
  3. Konishi H, *Shirakawa J, Arai M, Terauchi Y. Drug-induced hyperglycemia in the Japanese Adverse Drug Event Report Database: association of evelolimus use with diabetes. Endocr J. 66(6):571-574, 2019. 
  4. Ji Y, Sun S, Shrestha N, Darragh LB, Shirakawa J, Xing Y, He Y, Carboneau BA, Kim H, An D, Ma M, Oberholzer J, Soleimanpour SA, Gannon M, Liu C, Naji A, Kulkarni RN, Wang Y, Kersten S, Qi L. Toll-like receptors TLR2 and TLR4 block the replication of pancreatic β cells in diet-induced obesity. Nat Immunol. 20(6):677-686, 2019. 
  5. Miyazaki T, Shirakawa J, Nagakura J, Shibuya M, Kyohara M, Okuyama T, Togashi Y, Nakamura A, Kondo Y, Satoh S, Nakajima S, Taguri M, Terauchi Y. Influence of Timing of Insulin Initiation on Long-term Glycemic Control in Japanese Patients with Type 2 Diabetes: A Retrospective Cohort Study. Intern Med. 58(23):3361-3367, 2019.

*: corresponding author

#: co-first author

2018

  1. Shirakawa J, Terauchi Y. SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide. Ann Transl Med. 6(7):129, 2018.
  2. Kimura M, Kondo Y, Aoki K, Shirakawa J, Kamiyama H, Kamiko K, Nakajima S, Terauchi Y. A Randomized Controlled Trial of a Mini Low-Carbohydrate Diet and an Energy-Controlled Diet Among Japanese Patients with Type 2 Diabetes. J Clin Med Res. 10(3):182-188, 2018.
  3. Inoue H, *Shirakawa J, Togashi Y, Tajima K, Okuyama T, Kyohara M, Tanaka Y, Orime K, Saisho Y, Yamada T, Shibue K, Kulkarni RN, Terauchi Y. Signaling between pancreatic β-cells and macrophages via S100 calcium-binding protein A8 exacerbates β-cell apoptosis and islet inflammation. J Biol Chem. 293(16):5934-5946, 2018.
  4. Arai M, *Shirakawa J, Konishi H, Sagawa N, Terauchi Y. Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database. Diabetes Care. 41(9):e130-e132, 2018.
  5. Konishi H, *Shirakawa J, Tajima K, Okuyama T, Togashi Y, Takamine H, Kondo Y, Kunishita R, Terauchi Y. Effects of SGLT2 inhibition on eGFR and glomerular and tubular damage markers in Japanese patients with Type 2 diabetes. J Endocrinol Metab. 8(5):106-112, 2018. 

*: corresponding author

2017

  1. Shirakawa J, Terauchi Y. Glucose- or insulin resistance-mediated β-cell replication: PKCζ integrates the proliferative signaling. J Diabetes Investig. 8(2):149-151, 2017.
  2. Shirakawa J, Fernandez M, Takatani T, El Ouaamari A, Jungtrakoon P, Okawa ER, Zhang W, Yi P, Doria A, Kulkarni RN. Insulin signaling regulates the FoxM1/PLK1/CENP-A pathway to promote adaptive β-cell proliferation. Cell Metab. 25(4):868-882, 2017.
  3. Shirakawa J, De Jesus DF, Kulkarni RN. Exploring inter-organ crosstalk to uncover mechanisms that regulate β-cell function and mass. Eur J Clin Nutr. 71(7):896-903, 2017.
  4. Okuyama T, *Shirakawa J , Yanagisawa H, Kyohara M, Yamazaki S, Tajima K, Togashi Y, Terauchi Y. Identification of the matricellular protein Fibulin-5 as a target molecule of glucokinase-mediated calcineurin/NFAT signaling in pancreatic islets. Sci Rep. 7(1):2364, 2017.
  5. #Kawamori D, #Shirakawa J , Liew CW, Hu J, Morioka T, Duttaroy A, Burkey B, and Kulkarni RN. GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in βIRKO mice. Diabetologia. 60(8):1442-1453, 2017.
  6.  Tajima K, *Shirakawa J, Togashi Y, Yamazaki S, Okuyama T, Kyohara M, Konishi H, Terauchi Y. Metabolic recovery of lipodystrophy, liver steatosis, and pancreatic β cell proliferation after the withdrawal of OSI-906. Sci Rep. 7(1):4119, 2017.
  7. Tajima K, *Shirakawa J, Okuyama T, Kyohara M, Yamazaki S, Togashi Y, Terauchi Y. Effects of metformin on compensatory pancreatic β-cell hyperplasia in mice fed a high-fat diet. Am J Physiol Endocrinol Metab. 313(3):E367-E380, 2017.
  8. Johansson BB, Fjeld K, Solheim MH, Shirakawa J, Zhang E, Keindl M, Hu J, Lindqvist A, Døskeland A, Mellgren G, Flatmark T, Njølstad PR, Kulkarni RN, Wierup N, Aukrust I, Bjørkhaug L. Nuclear import of glucokinase in pancreatic beta-cells is mediated by a nuclear localization signal and modulated by SUMOylation. Mol Cell Endocrinol. 454:146-157, 2017.
  9. Kyohara M, *Shirakawa J, Okuyama T, Kimura A, Togashi Y, Tajima K, Hirano H, Terauchi Y.: Serum quantitative proteomic analysis reveals soluble EGFR to be a marker of insulin resistance in male mice and humans.  Endocrinology. 158(12):4152-4164, 2017.

*: corresponding author

#: co-first author

2016

  1. El Ouaamari A, Dirice E, Gedeon N, Hu J, Zhou JY, Shirakawa J, Hou L, Goodman J, Karampelias C, Qiang G, Boucher J, Martinez R, Gritsenko MA, De Jesus DF, Kahraman S, Bhatt S, Smith RD, Beer HD, Jungtrakoon P, Gong Y, Goldfine AB, Liew CW, Doria A, Andersson O, Qian WJ, Remold-O’Donnell E, Kulkarni RN. SerpinB1 Promotes Pancreatic β Cell Proliferation. Cell Metab. 23(1):194-205, 2016.
  2. Orime K, Shirakawa J, Togashi Y, Tajima K, Inoue H, Nagashima Y, Terauchi Y. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model. Eur J Pharmacol. 772:22-32, 2016.
  3. *Shirakawa J, Okuyama T, Kyohara M, Yoshida E, Togashi Y, Tajima K, Yamazaki S, Kaji M, Koganei M, Sasaki H, Terauchi, Y. DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid. Diabetol Metab Syndr. 8:16, 2016.
  4. Valdez IA, Dirice E, Gupta MK, Shirakawa J, Teo AK, Kulkarni RN. Proinflammatory cytokines induce endocrine differentiation in pancreatic ductal cells via STAT3-dependent NGN3 activation. Cell Rep. 19;15(3):460-70, 2016.
  5. Togashi Y, *Shirakawa J, Okuyama T, Yamazaki S, Kyohara M, Miyazawa A, Suzuki T, Hamada M, *Terauchi Y. Evaluation of the appropriateness of using glucometers for measuring the blood glucose levels in mice. Sci Rep. 6:25465, 2016.
  6. Shirakawa J, Kulkarni RN. ERRγ—A New Player in β Cell Maturation. Cell Metab. 23(5):765-767, 2016.
  7. #Takatani T, #Shirakawa J, Roe MW, Leech CA, Maier BF, Mirmira RG, Kulkarni RN. IRS1 deficiency protects β-cells against ER stress-induced apoptosis by modulating sXBP-1 stability and protein translation. Sci Rep. 6.28177, 2016.
  8. #Mezza T, #Shirakawa J, Martinez R, Hu J, Giaccari S, Kulkarni RN. Nuclear export of FoxO1 is associated with ERK signaling in β-cells lacking insulin receptors. J Biol Chem. 291(41):21485-21495, 2016.
  9. Shirakawa J, Kulkarni RN. Novel factors modulating human β-cell proliferation. Diabetes Obes Metab. Suppl 1:71-7, 2016.

*: corresponding author

#: co-first author

2015

  1. El Ouaamari A, Zhou JY, Liew CW, Shirakawa J, Dirice E, Gedeon N, Kahraman S, De Jesus DF, Bhatt S, Kim JS, Clauss TR, Camp DG 2nd, Smith RD, Qian WJ, Kulkarni RN. Compensatory islet response to insulin resistance revealed by quantitative proteomics. J Proteome Res. 14(8):3111-22, 2015.
  2. Bhatt S, Gupta MK, Khamaisi M, Martinez R, Gritsenko MA, Wagner BK, Guye P, Busskamp V, Shirakawa J, Wu G, Liew CW, Clauss TR, Valdez I, El Ouaamari A, Dirice E, Takatani T, Keenan HA, Smith RD, Church G, Weiss R, Wagers AJ, Qian WJ, King GL, Kulkarni RN. Preserved DNA damage checkpoint pathway protects against complications in long-standing type 1 diabetes. Cell Metab. 22(2):239-52, 2015.
  3. Gupta MK, Teo AK, Rao TN, Bhatt S, Kleinridders A, Shirakawa J, Takatani T, De Jesus DF, Windmueller R, Wagers AJ, Kulkarni RN. Excessive cellular proliferation negatively impacts reprogramming efficiency of human fibroblasts. Stem Cells Transl Med. 4(10):1101-8, 2015.
  4. Lee YJ, Liu C, Liao M, Sukhova GK, Shirakawa J, Abdennour M, Iamarene K, Andre S, Inouye K, Clement K, Kulkarni RN, Banks AS, Libby P, Shi GP. Deficiency of FcϵR1 increases body weight gain but improves glucose tolerance in diet-induced obese mice. Endocrinology. 156(11):4047-58, 2015.

2014

  1. Shirakawa J, Terauchi Y. Selective and sequential loss of transcriptional factors: a hallmark of β cell failure in type 2 diabetes? J Diabetes Investig. 5(4):359-61, 2014.
  2. Togashi Y, Shirakawa J, Orime K, Kaji M, Sakamoto E, Tajima K, Inoue H, Nakamura A, Tochino Y, Goshima Y, Shimomura I, Terauchi Y. β cell proliferation after a partial pancreatectomy is independent of IRS-2 in mice. Endocrinology. 155(5):1643-52, 2014.
  3. Shirakawa J, Okuyama T, Yoshida E, Shimizu M, Horigome Y, Tuno T, Hayasaka M, Abe S, Fuse M, Togashi Y, Terauchi Y. Effects of the antitumor drug OSI-906, a dual inhibitor of IGF-1 receptor and insulin receptor, on the glycemic control, β cell functions, and β cell proliferation in male mice. Endocrinology. 155(6):2102-1120, 2014.
  4. Shirakawa J, Murohashi Y, Okazaki N, Yamazaki S, Tamura T, Okuyama T, Togashi Y, Terauchi Y. Using miglitol at 30 min before meal is effective in hyperinsulinemic hypoglycemia after a total gastrectomy. Endocr J. 61(11):1115-23, 2014.

2013

  1. Orime K, Shirakawa J, Togashi Y, Tajima K, Inoue H, Ito Y, Sato K, Nakamura A, Aoki K, Goshima Y, Terauchi Y. Trefoil factor 2 promotes cell proliferation in pancreatic β cells through CXCR-4-mediated ERK1/2 phosphorylation. Endocrinology. 154(1):54-64. 2013.
  2. Tajima K, Shirakawa J, Togashi Y, Inoue H, Sato K, Orime K, Ito Y, Kaji M, Sakamoto E, Nakamura A, Aoki K, Goshima Y, Atsumi T, Terauchi Y. AMPK is involved in the regulation of incretin receptors expression in pancreatic islets under a low glucose concentration. Plos One. 8(5):e64633, 2013.
  3. Shirakawa J, Togashi Y, Sakamoto E, Kaji M, Tajima K, Orime K, Inoue H, Kubota N, Kadowaki T, Terauchi Y. Glucokinase activation ameliorates ER stress-induced apoptosis in pancreatic β cells. Diabetes. 62(10):3448-58, 2013.
  4. Tajima K, Nakamura A, Shirakawa J, Togashi Y, Orime K, Sato K, Inoue H, Kaji M, Sakamoto E, Ito Y, Aoki K, Nagashima Y, Atsumi T, Terauchi Y. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice. Am J Physiol Endocrinol Metab. 305(8):E987-98, 2013.

2012

  1. Iwasaki T, Tomeno W, Yoneda M, Inamori M, Shirakawa J, Imajo K, Kawashima K, Terauchi Y, Nakajima A. Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin. Hepatogastroenterology. 59(117):1522-5. 2012.
  2. Sato K, Nakamura A, Shirakawa J, Muraoka T, Togashi Y, Shinoda K, Orime K, Kubota N, Kadowaki T, Terauchi Y. Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance, beta cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet. Endocrinology. 153(3):1093-102. 2012.
  3. Nakamura A, Togashi Y, Orime K, Sato K, Shirakawa J, Ohsugi M, Kubota N, Kadowaki T, Terauchi Y. Control of beta cell function and proliferation in mice stimulated by small-molecule glucokinase activator under various conditions. Diabetologia. 55(6):1745-54. 2012.
  4. Shirakawa J, Togashi Y, Tajima K, Orime K, Kikuchi K, Miyazaki T, Sato K, Kimura M, Goshima Y, Terauchi Y. Plasminogen activator inhibitor-1 is associated with renal dysfunction independent of BMI and serum lipid levels in patients with type 2 diabetes. Diabetes Res Clin Pract. 97(1):e7-e10. 2012.
  5. Shirakawa J, Tanami R, Togashi Y, Tajima K, Orime K, Kubota N, Kadowaki T, Goshima Y,　Terauchi Y. Effects of liraglutide on β cell-specific glucokinase-deficient neonatal mice. Endocrinology. 153(7):3066-75. 2012.
  6. Kikuchi K, Nezu U, Inazumi K, Miyazaki T, Ono K, Orime K, Shirakawa J, Sato K, Koike H, Wakasugi T, Sato M, Kawakami C, Watanabe S, Yamakawa T, Terauchi Y. Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. J Atheroscler Thromb. 19(12):1093-101. 2012.

2011

  1. Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, Sakamoto E, Koganei M, Sasaki H, Nagashima Y, Amo K, Aoki K, Morimoto C, Takeda E, Terauchi Y. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes. 60(4):1246-57. 2011.
  2. Shirakawa J, Amo K, Ohminami H, Orime K, Togashi Y, Ito Y, Tajima K, Koganei M, Sasaki H, Takeda E, Terauchi Y. Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes. J Biol Chem. 286(29):25467-76. 2011.
  3. Iwasaki T, Yoneda M, Inamori M, Shirakawa J, Higurashi T, Maeda S, Terauchi Y, Nakajima A. Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology. 58(112):2103-5. 2011.

2010

  1. Kikuchi K, Nezu U, Shirakawa J, Sato K, Togashi Y, Kikuchi T, Aoki K, Ito Y, Kimura M, Terauchi Y. Correlations of fasting and postprandial blood glucose increments to the overall diurnal hyperglycemic status in type 2 diabetic patients: variations with levels of HbA1c. Endocr J.  2;57(3):259-66. 2010.

2009

  1. Aoki K, Ito Y, Saito K, Shirakawa J, Togashi Y, Satoh K, Muraoka T, Shinoda K, Masuda K, Kimura M, Terauchi Y. Comparison of pre- versus post-meal administration of voglibose in men with or without impaired glucose tolerance. Diabetes Res Clin Pract. 83(2):e31-2. 2009.
  2. *Shirakawa J, Takeshita T, Miyao M, Orimo S, Terauchi Y, Mizuno Y. Pituitary abscess with panhypopituitarism showing T1 signal hyperintensity of the marginal pituitary area: a non-invasive differential diagnosis of pituitary abscess and pituitary apoplexy. Intern Med. 48(6):441-6. 2009.

*: corresponding author

2008

  1. Wang Y, Shibuya K, Yamashita Y, Shirakawa J, Shibata K, Kai H, Yokosuka T, Saito T, Honda S, Tahara-Hanaoka S, Shibuya A. LFA-1 decreases the antigen dose for T cell activation in vivo. Int Immunol. 20(9):1119-27. 2008.

2006

  1. Shirakawa J, Wang Y, Tahara-Hanaoka S, Honda S, Shibuya K, Shibuya A. LFA-1-dependent lipid raft recruitment of DNAM-1 (CD226) in CD4+ T cell. Int Immunol. 18(6):951-7. 2006.

2005

  1. Shirakawa J, Shibuya K, Shibuya A. Requirement of the serine at residue 329 for lipid rafts recruitment of DNAM-1 (CD226). Int Immunol. 17(3):217-23. 2005.

2003

  1. Shibuya K, Shirakawa J, Kameyama T, Honda S, Tahara-Hanaoka S, Miyamoto A, Onodera M, Sumida T, Nakauchi H, Miyoshi H, Shibuya A. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J Exp Med. 198(12):1829-39. 2003.